Clinical Trial Update: Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluated dasatinib in combination with docetaxel for metastatic hormone-refractory prostate cancer; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Sprycel (dasatinib)
• Taxotere (docetaxel)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Metastatic Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-11-27